Novartis Applauds Move to Reimburse Families for Zolgensma & Making Connections with SMA

SMA News Today’s multimedia associate, Price Wooldridge, discusses how Novartis Pharmaceuticals Canada applauds the province of Quebec for its move to offer public reimbursement for the SMA gene therapy Zolgensma.

Also, making meaningful connections has become difficult for DeAnn Runge over the past several years. She explains why that is and shares some of her recent experiences.

Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/